Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the appointment of Lee Kalowski as Chief Financial Officer.
“We are delighted to welcome Lee to the Bicycle team at this exciting time for our company,” said Dr. Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “He brings a wealth of experience working with biotech companies at all stages of their evolution, both as a Wall Street research analyst and as a public company CFO, and his insights will prove invaluable as we continue to grow our business, expand our pipeline and move our lead candidate, BT1718, into clinical development.”
Prior to joining Bicycle, Mr. Kalowski served as the Chief Financial Officer of Tokai Pharmaceuticals, Inc., where he helped lead the company’s $105 million initial public offering in 2014. Previously, he was vice president, global biotechnology equity research at Credit Suisse, where he served as a senior research analyst covering the biotechnology sector. Before that, he worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group. Mr. Kalowski received a B.A. in biology and economics from Union College and an MBA from The Wharton School of the University of Pennsylvania.
“Bicycle has pioneered a revolutionary platform that has generated a new class of drugs designed to target diseases more effectively,” said Mr. Kalowski. “I am thrilled to be joining the company as the pipeline continues to expand and as the company transitions into a clinical-stage biotech company.”
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557